Clinical and cellular pharmacology in relation to solid tumours of childhood (Q35202886)

7 August 2017

1 reference

title

Clinical and cellular pharmacology in relation to solid tumours of childhood (English)

1 reference

7 August 2017

1 reference

Estlin EJ

1 reference

7 August 2017

Veal GJ

series ordinal

1 reference

7 August 2017

language of work or name

1 reference

1 August 2003

1 reference

7 August 2017

published in

Cancer Treatment Reviews

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

253-273

1 reference

Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Inhibition of RNA synthesis by actinomycin D: Characteristic dose-response of different RNA species

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Characterization of actinomycin-D-resistant CHO cell lines exhibiting a multidrug-resistance phenotype and amplified DNA sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Uptake in vivo and in vitro of actinomycin D by mouse leukemias as factors in survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics of actinomycin 0 in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Outcomes in low-risk babies treated with half-dose chemotherapy according to the Third National Wilms' Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

VINCRISTINE IN CHILDREN WITH MALIGNANT SOLID TUMORS

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Vincristine treatment of cancer in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Vincristine pharmacokinetics after repetitive dosing in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Vincristine disposition in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

ACTINOMYCIN D IN WILM'S TUMOUR: TREATMENT OF LUNG METASTASES

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Hepatotoxicity in patients treated according to the Nephroblastoma Trial and Study SIOP-9/GPOH

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Veno-occlusive disease of the liver in children treated for Wilms tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The prognostic value of MDR1 gene expression in primary untreated neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetic studies in the chemotherapy of neuroblastoma using the C1300 murine system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Effects of newly introduced chemotherapeutic agents on a cytogenetically highly malignant neuroblastoma, xenotransplanted in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Adriamycin in the treatment of childhood solid tumors.A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Chemotherapy of advanced neuroblastoma: does adriamycin contribute?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics of melphalan in children following high-dose intravenous injection.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Metabolism of oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Isophosphoramide Mustard and Its Mechanism of Bisalkylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The Partitioning of Phosphoramide Mustard and Its Aziridinium Ions among Alkylation and P−N Bond Hydrolysis Reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Cyclophosphamide pharmacokinetics in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Decreased half life of cyclophosphamide in patients under continual treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Progress and controversy in the treatment of childhood rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Role of glutathione in cisplatin resistance in osteosarcoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Clinical pharmacokinetics of carboplatin in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics and acute renal effects of continuously infused carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Cisplatin pharmacokinetics in children with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors*

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A limited sampling model for the pharmacokinetics of etoposide given orally.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Prognostic Factors in Patients with Localized Ewing’s Sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up-front" study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900109-3

7 January 2021

10.1016/S0305-7372(02)00109-3

Identifiers

DOI

1 reference

7 August 2017

1 reference